Senhwa Biosciences, Inc.

6492

TW0006492002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 2026-06-29			5-day change	1st Jan Change
42.60 ^TWD	+0.83%		-0.93%	-3.18%

May. 12	Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 05	Senhwa Biosciences, Inc. Launches Global Multi-Center Clinical Trial for Cx-5461 and Tislelizumab Combination	CI

Senhwa Biosciences, Inc. announced that it expects to receive TWD 500 million in funding from Global Emerging Markets

Published on 04/14/2026 at 05:05 am EDT

S&P Capital IQ

SENHWA BIOSCIENCES, INC.

+0.83%

Senhwa Biosciences, Inc. has entered into an agreement with Global Emerging Markets for gross proceeds of TWD 500 million on April 14, 2026.

Latest news about Senhwa Biosciences, Inc.

May. 12	Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 05	Senhwa Biosciences, Inc. Launches Global Multi-Center Clinical Trial for Cx-5461 and Tislelizumab Combination	CI
Apr. 14	Senhwa Biosciences and Gem Yield Bahamas Limited Sign Memorandum of Understanding for Up to TWD 500 Million Strategic Funding	CI
Apr. 14	Senhwa Biosciences, Inc. announced that it expects to receive TWD 500 million in funding from Global Emerging Markets	CI
Mar. 17	Senhwa Biosciences Inc Demonstrates Breakthrough For CX-5461 In Photodynamic Therapy	CI
Mar. 11	Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 03	Senhwa Biosciences And CellType Sign Strategic Memorandum of Understanding to Accelerate Evolution Of CX-4945 Into Version 2.0	CI
Dec. 28	Senhwa Biosciences, Inc. Aims At Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy	CI
Dec. 28	Senhwa?s CX-5461 with Astrazeneca/Daiichi Sankyo?s ADC, Trastuzumab Deruxtecan in Phase 1b HER2+ and Breast Cancer Trial; NCI Submits FDA Application	CI
Dec. 23	Senhwa Biosciences, Inc Outlines Continued Progress Across Its Ai-Enabled Drug Development Platform	CI
Dec. 11	Senhwa Biosciences, Inc. and BeOne Medicines Announces Clinical Supply Agreement to Address the Challenge of Cold Tumors	CI
Nov. 12	Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-24	EM stocks rise, Czech crown slips as central bank verdict looms	RE
25-09-05	Senhwa Biosciences, Inc. CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value	CI
25-08-06	Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

Chart Senhwa Biosciences, Inc.

Duration

Period

6492: Dynamic Chart

Senhwa Biosciences, Inc. is a Taiwan-based company principally engaged in the research and development of anti-cancer new drugs and special drug substances. The Company's main development projects include the CX-5461, for the treatment of hematologic cancers and breast cancers, as well as the CX-4945, for the treatment of cholangiocarcinoma. The Company has not generated any revenues yet.

Employees

Sector

Biotechnology & Medical Research

More about the company